報價延遲最少15分鐘:2026/04/22 03:20 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.13 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.81/-0.01
|
|
企業價值
102.82M
|
| 資產負債 |
|
每股賬面淨值
0.30
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
65.34K
|
|
每股收益
0.12
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP. |
